BHVN — Biohaven Income Statement
0.000.00%
Last trade - 00:00
- $3.19bn
- $2.81bn
- 30
- 12
- 83
- 37
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Total Operating Expenses | 115 | 219 | 568 | 436 |
Operating Profit | -115 | -219 | -568 | -436 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -119 | -212 | -570 | -410 |
Provision for Income Taxes | ||||
Net Income After Taxes | -119 | -214 | -570 | -408 |
Net Income Before Extraordinary Items | ||||
Net Income | -119 | -214 | -570 | -408 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -119 | -214 | -570 | -408 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -1.84 | -3.32 | -8.36 | -5.73 |